Tidal Therapeutics Overview
- Year Founded
-
2019
- Status
-
Acquired/Merged
- Employees
-
9
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$470M
Tidal Therapeutics General Information
Description
Operator of a preclinical-stage company intended to utilize a novel mRNA-based approach to in vivo reprogramming of immune cells. The company focuses on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases, thus providing the healthcare industry with pre-clinical programs for cancer indications.
Contact Information
Corporate Office
- 700 Main Street
- Cambridge, MA 02139
- United States
Corporate Office
- 700 Main Street
- Cambridge, MA 02139
- United States
Tidal Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 09-Apr-2021 | $470M | Completed | Pre-Clinical Trials | ||
| 3. Early Stage VC | 01-Jan-2020 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 01-Jul-2019 | Completed | Pre-Clinical Trials | |||
| 1. Accelerator/Incubator | Completed | Pre-Clinical Trials |
Tidal Therapeutics Patents
Tidal Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024397704-A1 | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof | Pending | 13-Dec-2023 | ||
| EP-4824036-A1 | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof | Pending | 13-Dec-2023 | ||
| US-20250205169-A1 | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof | Pending | 13-Dec-2023 | ||
| WO-2025128902-A1 | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof | Inactive | 13-Dec-2023 | ||
| WO-2024163905-A1 | Hsc-specific antibody conjugated lipid nanoparticles and uses thereof | Inactive | 03-Feb-2023 | A61K47/6929 |
Tidal Therapeutics Signals
Tidal Therapeutics Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| LabCentral | Accelerator/Incubator | |||
| MRL Ventures Fund | Corporate Venture Capital | Minority | ||
| Mission BioCapital | Venture Capital | Minority | ||
| Myeloma Investment Fund | Not-For-Profit Venture Capital | Minority |
Tidal Therapeutics FAQs
-
When was Tidal Therapeutics founded?
Tidal Therapeutics was founded in 2019.
-
Where is Tidal Therapeutics headquartered?
Tidal Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Tidal Therapeutics?
Tidal Therapeutics has 9 total employees.
-
What industry is Tidal Therapeutics in?
Tidal Therapeutics’s primary industry is Drug Delivery.
-
Is Tidal Therapeutics a private or public company?
Tidal Therapeutics is a Private company.
-
What is the current valuation of Tidal Therapeutics?
The current valuation of Tidal Therapeutics is .
-
What is Tidal Therapeutics’s current revenue?
The current revenue for Tidal Therapeutics is .
-
Who are Tidal Therapeutics’s investors?
AbbVie Ventures, LabCentral, MRL Ventures Fund, Mission BioCapital, and Myeloma Investment Fund are 5 of 6 investors who have invested in Tidal Therapeutics.
-
When was Tidal Therapeutics acquired?
Tidal Therapeutics was acquired on 09-Apr-2021.
-
Who acquired Tidal Therapeutics?
Tidal Therapeutics was acquired by Sanofi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process